#globalhealthcarecompany — Public Fediverse posts

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Approval Addresses High Unmet Medical Need and Further Advances Viatris’ Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026…
#EuropeSays #Japan #JP #controlledsubstance #excessivedaytimesleepiness #globalhealthcarecompany #narcolepsy #OSAS #patients #treatmentoption #Viatris #WAKIX
https://www.europesays.com/japan/92567/

ESTEVE’S EXPANSION AND GROWTH IN EU AND USA ACCELERATES ITS TRANSFORMATION INTO A GLOBAL HEALTHCARE COMPANY

New assets in both businesses – Pharma and CDMO – fuel double-digit growth in net revenues and EBITDA…
#Europe #EU #CDMO #developmentcapabilities #ESTEVE #EuropeanUnion #globalhealthcarecompany #growthstrategy #inorganicgrowth #strategyexecution
https://www.europesays.com/europe/30951/

https://www.europesays.com/ch/26081/ Roche, stakeholders urge Africa to treat health as economic investment #EastAndWestAfrica #GlobalHealthcareCompany #Kenya #Nairobi #Roche #RocheAndAfricanHealthLeaders #Roche’sAfricaBreastCancerAmbition

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region https://www.byteseu.com/1454406/ #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #OSAS #Pharma #RegulatoryApproval #StatusEpilepticus #Viatris

https://www.alojapan.com/1392924/viatris-completes-acquisition-of-aculys-pharma-including-exclusive-rights-to-pitolisant-in-japan-and-to-spydia-in-japan-and-certain-other-markets-in-the-asia-pacific-region/ Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #JapanNews #news #OSAS #pharma #RegulatoryApproval #StatusEpilepticus #Viatris Strengthens Viatris’ Presence in Japan With the Addition of Two Innovative Assets Targeting Ar